Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals.
M Clerici, N I Stocks, R A Zajac...
https://pubmed.ncbi.nlm.nih.gov/2524668Completed
All Genders
Healthy Volunteers
ID00001210
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
Led by National Cancer Institute (NCI) · Updated on 2008-03-04
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.
CONDITIONS
Official Title
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
Who Can Participate
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Inclusion criteria for the at risk group will be a statement from the donor that he is an active homosexual or bisexual.
Homosexual donors must not have AIDS.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892
Status Unknown
Loading map...
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro.
M Clerici, D R Lucey, J A Berzofsky...
https://pubmed.ncbi.nlm.nih.gov/7903123ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids.
L A Pinto, J Sullivan, J A Berzofsky...
https://pubmed.ncbi.nlm.nih.gov/7635981